The move has been triggered by the shortage of drugs — most of them
supplied by Indian generic drug companies — that the US faces during
the Covid-19 pandemic. The Indian Pharmaceutical Alliance has asked
the FDA last month to find a solution for inspecting the manufacturing
plants of its members.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-looks-for-ways-to-speed-up-plant-inspections/articleshow/75766711.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment